June 5, 2018

First Canadian Calciphylaxis Subject to Participate in the CALISTA

Scottsdale, Arizona June 5, 2018 – Hope Pharmaceuticals today announced enrollment of the first Canadian subject to participate in the CALISTA clinical study that is evaluating Sodium Thiosulfate Injection for the treatment of calciphylaxis (calcify uremic arteriolopathy, CUA).

Read More